• Flanders Investment & Trade
  • Team Vesalius

Renowned virologist and emeritus professor, Dr. Erik De Clercq began his medical career in 1966. Under his leadership, scientists at the Rega Institute for Medical Research discovered some of the first anti-HIV medications.

Erik De Clercq

KU Leuven

Emeritus Professor

De Clercq played a central role in developing the paradigm-shifting concept of combination therapy for HIV, which is still the most effective treatment strategy for HIV/AIDS patients today. Over his prodigious career, De Clercq’s research has focused on the development of new therapies, particularly the development of new agents that fight viral infections.

He is widely recognized for his seminal work in the field of nucleotide analogs, the first broad-spectrum antivirals, sparking a new era in antiviral development.

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?